Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) shares, rose in value, with the stock price down by -0.75% to the previous day’s close as strong demand from buyers drove the stock to $0.24.
Actively observing the price movement in the last trading, the stock closed the session at $0.24, falling within a range of $0.2358 and $0.2461. The value of beta (5-year monthly) was 2.837. Referring to stock’s 52-week performance, its high was $1.48, and the low was $0.20. On the whole, ADAP has fluctuated by -46.96% over the past month.
With the market capitalization of Adaptimmune Therapeutics Plc ADR currently standing at about $60.96 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-23.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 38.98M, with a low estimate of 3.01M and a high estimate of 13.3M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 6.55M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ADAP’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of ADAP currently trading nearly -3.21% and -41.99% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 37.80, while the 7-day volatility ratio is showing 10.89% which for the 30-day chart, stands at 19.04%. Furthermore, Adaptimmune Therapeutics Plc ADR (ADAP)’s beta value is 2.69, and its average true range (ATR) is 0.04.
A comparison of Adaptimmune Therapeutics Plc ADR (ADAP) with its peers suggests the former has fared considerably weaker in the market. ADAP showed an intraday change of -0.75% in last session, and over the past year, it shrunk by -76.87%%.
Data on historical trading for Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) indicates that the trading volumes over the past 10 days have averaged 1.34 and over the past 3 months, they’ve averaged 1.70 million. According to company’s latest data on outstanding shares, there are 255.94 million shares outstanding.
Nearly 11.49% of Adaptimmune Therapeutics Plc ADR’s shares belong to company insiders and institutional investors own 37.36% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 5.45 million shares as on 2025-03-31, resulting in a short ratio of 2.26. According to the data, the short interest in Adaptimmune Therapeutics Plc ADR (ADAP) stood at 317.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 6.36 million. The stock has fallen by -55.78% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ADAP stock heading into the next quarter.
